Follow
Dizlin Pharmaceuticals AB
Dizlin Pharmaceuticals AB (Dizlin) is a medical research company active in the development of medical drugs for treatment of diseases of the central nervous system. Dizlin is currently concentrating its resarch resources on the development of medical drugs for treatment of Parkinson’s Disease (PD). Research and development are based at the Sahlgrenska Academy, Gothenburg, Sweden. The Sahlgrenska Academy was also the base for Professor Emeritus Arvid Carlsson’s research, where he discovered that dopamine is Dizlin Pharmaceuticals AB (Dizlin) is a medical research company active in the development of medical drugs for treatment of diseases of the central nervous system. Dizlin is currently concentrating its resarch resources on the development of medical drugs for treatment of Parkinson’s Disease (PD). Research and development are based at the Sahlgrenska Academy, Gothenburg, Sweden. The Sahlgrenska Academy was also the base for Professor Emeritus Arvid Carlsson’s research, where he discovered that dopamine is a neurotransmitter in the brain and not just a precursor of noradrenaline. Arvid Carlsson was awarded the Nobel Prize in medicine in the year of 2000 for his pioneering research, which also paved the way for using the dopamine precursor levodopa in the treatment of PD. Ever since then, levodopa has been the primary medical substance used in the treatment of PD. Arvid Carlsson was concerned about the fact that oral intake of levodopa eventually leads to, so called, on-off symptoms, characterized by rapid shifts between hypokinesia (decreased motility) and involuntary dyskinesias (hyper mobility) – called ”On-Off” – and he was therefore enthusiastic about Dizlin’s research, which offers a way to substantially reduce severe On-Off symptoms. Arvid Carlsson was a member of Dizlin’s Board of Directors until he passed away in the spring of 2018.

Read more

Current instruments
Type
Ticker
ISIN
SHARE
News
Nothing to display for this company
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
Details of share in Dizlin Pharmaceuticals AB with ticker
Status
Active
Order book id
Amount of instruments
Par value
Market cap
Currency
Terms
Type
Price
Pre-money valuation
Time
Files
Listing
2020
-
Listing of Dizlin Pharmaceuticals AB
People
Leif Bring
CEO
Roger Svensson
Board member
Elias Eriksson
Board member
Anders Stenström
Board member
Nil Dizdar Segrell
Board member
Staffan Schüberg
Board member
Leif Bring
Board member
Company Details
Sector
Website

Address
C/O Sahlgrenska Science Park
Zip code
413 90
City/district
Göteborg
Country
Sweden (SE)
Registration number
556644-3635
LEI code
5493000DB4N0PCR6PJ88
First trade date
Registration date
16 May 2003
Short name
Dizlin Pharmaceuticals

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date